Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New mRNA vaccine could stop lyme disease in its tracks

NCT ID NCT07561294

Vaccine Sponsor: ModernaTX, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 04, 2026 · Updated 2 times

Summary

This study tests an experimental mRNA vaccine (mRNA-1982) designed to prevent Lyme disease, which is spread by tick bites. About 350 healthy adults aged 18 to 70 will receive either the vaccine or a placebo to check for safety and immune response. The goal is to find the best dose that triggers strong protection against the bacteria that causes Lyme disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

366 people

The number who actually took part.

Started

Apr 2026

Expected to finish

Nov 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: * In good general health in the opinion of the investigator as determined by medical evaluation including medical history and physical examination at screening. * Contraceptive use by participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Key Exclusion Criteria: * History of anaphylaxis or severe hypersensitivity reaction requiring medical intervention after receipt of any mRNA vaccine or therapeutic or any components of an mRNA vaccine or therapeutic. * Have chronic illness related to Lyme disease or an active symptomatic Lyme disease infection as suspected or diagnosed by a physician. * Received treatment for Lyme disease within the prior 3 months. * Previously vaccinated against Lyme disease or participated in the past in any vaccine study for Lyme disease. * Had a tick bite within 4 weeks prior to Day 1. Note: Additional inclusion/exclusion criteria may apply, per protocol.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lyme disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Lyme disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lyme disease

Contacts and locations

Locations

  • Bluewater Clinical Research Group Inc.

    Sarnia, Ontario, N7T 4X3, Canada

  • Colchester Research Group

    Truro, Nova Scotia, B2N 1L2, Canada

  • Diex Recherche Inc. - Division Joliette

    Joliette, Quebec, J6E 6A9, Canada

  • Diex Recherche Inc. - Division Quebec

    Québec, G1V 4T3, Canada

  • Diex Recherche Inc. - Division Sherbrooke

    Sherbrooke, Quebec, J1L 0H8, Canada

  • Diex Recherche Inc. - Division Victoriaville

    Victoriaville, Quebec, G6P 3Z8, Canada

  • Dr. Anil K. Gupta Medicine Professional Corporation Inc.

    Toronto, Ontario, M9V 4B4, Canada

  • Stouffville Medical Research Institute Inc.

    Stouffville, Ontario, L4A 1H2, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.